254 results on '"El-Rayes B"'
Search Results
2. Institutional use of dose-adjusted modified (m2) FOLFIRINOX in older adults with pancreatic cancer
3. 4P Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
4. 84P Racial disparities in phase I lung cancer clinical trials
5. Toxicity Following Multimodal Treatment of Pancreatic Cancer
6. 172P HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
7. SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
8. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer
9. PD-019 ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
10. PD-4 A phase I trial of trifluridine/tipiracil in combination with nanoliposomal irinotecan in advanced GI cancers
11. SIOG2023-1-P-211 - Institutional use of dose-adjusted modified (m2) FOLFIRINOX in older adults with pancreatic cancer
12. P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates
13. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
14. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis
15. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
16. A phase II study of carboplatin and paclitaxel in esophageal cancer
17. Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer
18. Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
19. Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice
20. Effect of Neoadjuvant SBRT or Chemoradiation on Nodal Positivity for Resected Pancreatic Adenocarcinoma
21. The Effect of Neoadjuvant Radiotherapy on Tumor Regression Grade in Resected Pancreatic Adenocarcinoma
22. Intratumoral interleukin-6 and myeloid cell subsets within the cholangiocarcinoma tumor microenvironment
23. Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
24. Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)
25. Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
26. A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)
27. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
28. Optimal Treatment Phase Selection Based on a 4DCT Deformable Registration for Stereotactic Body Radiation Therapy in Pancreatic Cancer
29. A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
30. Designing a broad-spectrum integrative approach for cancer prevention and treatment
31. 2028P - Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice
32. 721P - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
33. Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)
34. A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy
35. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer
36. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin
37. 1221P - Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
38. 133P - Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)
39. O-009 - A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)
40. LBA-002 - A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
41. A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)
42. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis
43. Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: surveillance, epidemiology and end results database vs. tertiary cancer center
44. Prospective open-label single center study of safety and efficacy of glass-based Y90 radioembolization for infiltrative HCC with PVT
45. Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma and the effect of resin-based Yttrium-90 radioembolization: surveillance, epidemiology and end results database vs. tertiary cancer center
46. 464PD - A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy
47. 3:18 PMAbstract No. 130 - Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin
48. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer
49. Update with longitudinal analysis of quality of life assessment after doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC)
50. Longitudinal quality of life assessment of patients with hepatic metastatic colorectal adenocarcinoma after treatment with transarterial radioembolization Yttrium-90 therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.